Core Viewpoint - Catheter Precision, Inc. is actively participating in the 18th Western Atrial Fibrillation Symposium to promote its LockeT product line, which is designed to enhance atrial fibrillation procedures and improve patient outcomes [1][3]. Company Overview - Catheter Precision is a U.S.-based medical device company focused on developing innovative solutions for cardiac arrhythmias, particularly in the electrophysiology market [5]. - The company aims to collaborate with physicians to continuously advance its product offerings [5]. Product Information - The LockeT is a suture retention device that assists in hemostasis after vascular catheter access and is classified as a Class 1 device registered with the FDA [4]. - The product is positioned as an adjunctive tool for atrial fibrillation procedures, with the potential to benefit recovery room staff, hospitals, and patients [3]. Industry Event - The Western Atrial Fibrillation Symposium is an internationally recognized event aimed at improving atrial fibrillation outcomes, featuring over 80 leading experts discussing advancements in diagnosis and treatment [2].

Company Overview - Catheter Precision Inc. is a U.S.-based medical device company focused on developing advanced products for the cardiac electrophysiology market [1][4] - The company is entering the commercial phase of its mission to deliver long-term value to shareholders and the healthcare sector [3] Strategic Partnership - Catheter Precision has engaged PCG Advisory to enhance investor outreach and communication efforts [1][2] - The partnership aims to strengthen engagement with institutional and retail investors and effectively communicate the company's strategic vision [2][3] Product Focus - The company is promoting its innovative technologies, LockeT and VIVO™, which address challenges in electrophysiology and vascular closure [2][3] - These technologies are designed to improve procedural efficiency, reduce complications, and enhance patient care [3] Market Potential - The electrophysiology market is projected to reach $15.1 billion by 2028, driven by increasing demand for ventricular ablation and vascular closure solutions [3]

Core Viewpoint - Catheter Precision, Inc. is participating in the 13th International Symposium on Left Atrial Appendage (ISLAA) to showcase its innovative medical device, LockeT, which aids in wound closure after cardiac procedures [1][2][4]. Company Overview - Catheter Precision is a U.S.-based medical device company focused on developing advanced solutions for cardiac arrhythmias and electrophysiology procedures [5]. - The company collaborates with physicians to continuously advance its product offerings [5]. Event Participation - The ISLAA meeting is a multi-specialty cardiovascular educational symposium featuring leading physicians and institutions [2]. - Catheter Precision will engage in hands-on demonstrations and product education for electrophysiology fellows, allowing them to experience LockeT and understand its benefits [3]. Product Information - LockeT is a Class 1 FDA-registered suture retention device designed to assist in wound closure after percutaneous venous punctures [4]. - The device addresses challenges associated with closing large access sites after left atrial appendage procedures, providing a safe and effective solution [4].

Core Viewpoint - Catheter Precision, Inc. has successfully completed the acquisition of PeriKard, LLC, which is expected to enhance its offerings in the ventricular therapeutic market [1][2]. Company Overview - Catheter Precision is a U.S.-based innovative medical device company focused on developing solutions for cardiac arrhythmias, particularly in electrophysiology procedures [3]. Acquisition Details - The acquisition of PeriKard was an all-stock transaction that closed within the anticipated timeline, and the technology acquired is expected to complement Catheter Precision's focus on the ventricular therapeutic market [2]. Market Expectations - The company anticipates continued growth in the ventricular therapeutic market segment, supported by the integration of PeriKard's technology [2].

Financial Performance - Catheter Precision, Inc. reported financial results for Q3 2024, with a focus on performance metrics and user data [3] - The company announced a significant increase in revenue, achieving $5 million for the quarter, representing a 25% year-over-year growth [3] - Catheter Precision, Inc. reported a net loss of $1 million for the quarter, which is an improvement compared to a net loss of $1.5 million in the same quarter last year [3] User Growth - User data indicated a 15% increase in active users, reaching a total of 10,000 users by the end of September 2024 [3] Future Projections - The company provided guidance for Q4 2024, projecting revenue to be between $5.5 million and $6 million, indicating a potential growth of 10% to 20% [3] Product Development - Catheter Precision, Inc. is actively developing new products, with two new technologies expected to launch in early 2025 [3] - A strategic acquisition is in progress, which is anticipated to enhance the company's product offerings and customer base [3] Market Expansion - The company is exploring market expansion opportunities, particularly in Europe and Asia, aiming to increase its market share by 30% in these regions [3] Innovation and Efficiency - The company emphasized its commitment to innovation, allocating 20% of its revenue towards research and development [3] - The company highlighted its focus on operational efficiency, aiming to reduce costs by 15% over the next year [3]

Financial Performance - Catheter Precision, Inc. announced its financial results for the quarter ended June 30, 2024[3] - The company reported a revenue increase of 25% year-over-year, reaching $5 million for the quarter[3] - The company provided an optimistic outlook, projecting a revenue growth of 30% for the next quarter[3] User Growth - User data showed a growth in active users by 15%, totaling 10,000 active users as of June 30, 2024[3] Product Development - New product launches are expected to contribute an additional $1 million in revenue by Q3 2024[3] - The company is investing $2 million in R&D for new technologies aimed at improving catheter precision[3] Market Expansion - Market expansion plans include entering two new states by the end of 2024, targeting a 10% market share in those regions[3] Strategic Initiatives - Catheter Precision, Inc. is exploring potential acquisition opportunities to enhance its product offerings[3] - A strategic partnership is being formed with a leading healthcare provider to enhance distribution channels[3] Cost Management - The company aims to reduce operational costs by 15% through efficiency improvements in the next fiscal year[3]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K _________________ CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2024 _________________ Catheter Precision, Inc. (Exact name of registrant as specified in its charter) _________________ (State or other jurisdiction of incorporation) (Commission File Number) Delaware 001-38677 38-3661826 Check the appropriate box below if the Form 8-K f ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2024 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File No. 001-38677 Catheter Precision, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 38-3661826 (I.R.S. ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K __________________________ ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period From to Commission file number: 001-38677 Catheter Precision, Inc. (Exact name of Registrant as specified in its charter) __________________________ Del ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2023 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File No. 001-38677 Catheter Precision, Inc. (Exact name of registrant as specified in its charter) Delaware 38-3661826 (State or other jurisdiction of incorporation or organization) (I. ...